Angiotensin II type 1 receptor blockers.
Burnier
M
M
Division of Hypertension and Vascular Medicine, CHUV, Lausanne, Switzerland. Michel.Burnier@chuv.hospvd.ch
D000803:Angiotensin I / Q000378:metabolism; D000804:Angiotensin II / Q000378:metabolism; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology; D001667:Binding, Competitive; D001713:Biphenyl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D015195:Drug Design; D006801:Humans; D000077405:Irbesartan; D019808:Losartan / Q000494:pharmacology; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D011485:Protein Binding; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin / Q000145:classification / Q000502:physiology; D012084:Renin-Angiotensin System / Q000187:drug effects; D012504:Saralasin / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D044139:Receptor, Angiotensin, Type 2; D011945:Receptors, Angiotensin; D013777:Tetrazoles; D000804:Angiotensin II; D000068756:Valsartan; D000803:Angiotensin I; D007703:Peptidyl-Dipeptidase A; D012504:Saralasin; D014633:Valine; D000077405:Irbesartan; D019808:Losartan; C077793:candesartan cilexetil